Biogen Idec Inc. said Tuesday its profit jumped 34 percent in the third quarter due to lower amortization costs and increased sales of its multiple sclerosis drug Tysabri.
By THE ASSOCIATED PRESS, NY Times: Business
Tue, 10/20/2009 - 5:58am